Agreed
This web only uses its own cookies for technical purposes, it does not collect or transfer personal data of users without their knowledge.

Ready to market products

Potential License Out Opportunities
LUTRATE® Depot 3.75 mg

LUTRATE® Depot 3.75 mg

1 Month

Leuprolide Acetate

More details

LUTRATE® Depot 22.5mg

LUTRATE® Depot 22.5mg

3 Months

Leuprolide Acetate

More details

Ganirelix

Ganirelix

Ganirelix

More details

Teriparatide Pen

Teriparatide Pen

Teriparatide

More details

NICTUR® Oral Solution

NICTUR® Oral Solution

Desmopressin360 µg/ml

More details

 Carbetocina GP-PHARM

Carbetocina GP-PHARM

Carbetocin

More details

Octreotide GP-Pharm

Octreotide GP-Pharm

Octreotide Acetate

More details

Somatostatin GP-Pharm

Somatostatin GP-Pharm

Somatostatin

More details

Leuprolide Depot 7.5mg

Leuprolide Depot 7.5mg

Leuprolide Acetate

More details

Triptorelin 3.75mg

Triptorelin 3.75mg

1 Month

Triptorelin Acetate

More details

Irinotecan GP-Pharm

Irinotecan GP-Pharm

Irinotecan

More details

Oxaliplatin GP-Pharm

Oxaliplatin GP-Pharm

Oxaliplatin

More details

Gemcitabine GP-Pharm

Gemcitabine GP-Pharm

Gemcitabine

More details

Docetaxel GP-Pharm

Docetaxel GP-Pharm

Docetaxel

More details


Licensed-in products

For the Spanish Market
ACORE®

ACORE®

Tadalafil

More details

AMENUR®

AMENUR®

Anastrozole

More details

WIBICAL®

WIBICAL®

Bicalutamide

More details

GALDAR®

GALDAR®

Letrozole

More details

ZUANDOL®

ZUANDOL®

Sildenafil

More details

ZUANTRIP®

ZUANTRIP®

Tamsulosin

More details

GEPEX®

GEPEX®

Exemestane

More details


Research Projects

Opening Partnering for Co-Development & License
Icatibant is a synthetic decapeptide with a structure similar to bradykinin, but with 5 non-proteinogenic amino acids. It is used for symptomatic treatment of acute attacks of Hereditary AngioEdema (HAE)
LUTRATE® Depot Semestral (45,0 mg) es una nueva formulación de liberación prolongada de acetato de leuprorelina, un agonista de la LHRH, que se utiliza para el tratamiento de cáncer de próstata avanzado. El producto ha completado su desarrollo preclínico y está listo para entrar en las fases clínicas.

The content of the website you are trying to access may be considered as advertising regarding prescription medicines.

According to Spanish Royal Order 1416/1994 of 25 June regulating the advertising of medicinal products for human use and the Law 29/2006 on the guarantees and rational use of medicines and health products, in this section GP Pharm S.A. can only offer advertising content of prescription medicines to health personnel authorized to prescribe or dispense medicines.

The content of the website might contain information about drugs, medicines and/or therapeutic applications not approved in Spain.

I am a health professional authorized to prescribe or dispense, or a pharma company professional.

Accept
Cancel
Back to Top